Supplements

EEG-based measures show good to excellent test-retest reliability in clinical high risk for psychosis and control participants, supporting their use in CHR studies.

In an interim analysis of the AMP SCZ Program, EEG-based measures (including MMN, P300, 40-Hz ASSR, and resting PSD) demonstrated generally good to excellent test-retest reliability in CHR (n=654) and control (n=87) participants, with mean G-coefficients of 0.72 and 0.71, respectively. Small systematic decreases in measure magnitudes over sessions were observed, consistent with habituation effects.

1 min read•Updated Jul 7, 2026•0 RCTs•View structured evidence →
Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

EEG-based measures show good to excellent test-retest reliability in clinical high risk for psychosis and control participants, supporting their use in CHR studies. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).

The Claim

EEG-based measures show good to excellent test-retest reliability in clinical high risk for psychosis and control participants, supporting their use in CHR studies.

This conclusion is most relevant to: Individuals at clinical high risk for psychosis (CHR; n=654) and community controls (CON; n=87).

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. (Schizophrenia (Heidelberg, Germany), 2025) —

How It Works

The proposed biological pathway:

  • ▸EEG measures recorded across two sessions (baseline and month-2 follow-up)
  • ▸Generalizability coefficients calculated to assess reliability
  • ▸Paired t-tests used to assess changes over sessions
  • ▸Result: Good to excellent reliability with small habituation effects

Who Might Benefit

Evidence fit by population:

  • ▸Individuals at clinical high risk for psychosis (CHR; n=654) and community controls (CON; n=87)

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Interim analysis with limited follow-up duration (2 months)
  • ▸Small control group (n=87) relative to CHR group (n=654)

Frequently Asked Questions

What EEG measures were tested in this study?▼

The study tested mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response (ASSR), and resting EEG power spectral density (PSD) for traditional frequency bands.

How reliable were the EEG measures in clinical high risk individuals?▼

Generalizability coefficients were generally good to excellent, with a mean of 0.72 and range of 0.49-0.85 in the CHR group.

Did the EEG measures change over time?▼

Yes, small but significant decreases were observed over sessions for MMN, auditory and visual target P3b, visual novel P3a, and 40-Hz ASSR, consistent with habituation effects.

What is the Accelerating Medicines Partnership Schizophrenia Program?▼

It is a research program launched to address the need for safer, effective medications for individuals at clinical high risk for psychosis by developing biomarkers and novel treatments.

References

  1. 1.Mathalon DH, Nicholas S, Roach BJ, Billah T, Lavoie S, Whitford T, Hamilton HK, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión RE, Damiani S, Dzafic I, Ebdrup BH, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin EA, Mayol-Troncoso R, Niznikiewicz MA, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf DR, Rogers J, Salisbury DF, Shaik R, Shankman S, Stevens MC, Suen YN, Swann NC, Tang X, Thompson JL, Tso I, Wenzel J, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Castillo-Passi RI, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mittal VA, Nordentoft M, Pearlson GD, Perez J, Perkins DO, Powers AR, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Upthegrove R, Verma SK, Wang J, Wolf DH, Zhang T, Bouix S, Pasternak O, Cho KK, Coleman MJ, Dwyer D, Nunez A, Tamayo Z, Wood SJ, Kahn RS, Kane JM, McGorry PD, Bearden CE, Nelson B, Woods SW, Shenton ME, Light GA. “The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures..” Schizophrenia (Heidelberg, Germany), 2025. PMID: 40480970 DOI: 10.1038/s41537-025-00622-0
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.